Welcome to our dedicated page for PHIBRO ANIMAL HEALTH SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PHIBRO ANIMAL HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PHIBRO ANIMAL HEALTH's regulatory disclosures and financial reporting.
Bendheim Daniel M reported acquisition or exercise transactions in this Form 4 filing.
PHIBRO ANIMAL HEALTH CORP reported that President and CEO Daniel M. Bendheim received a grant of 300,000 Performance Stock Units. Each unit represents a contingent right to one share of Class A Common Stock.
The performance stock units will vest, or be forfeited in full or in part, on June 30, 2031. Vesting depends on achieving specified stock price performance measured as of that date and on Bendheim’s continued employment through that time.
Phibro Animal Health Corporation appointed Daniel (Dani) Bendheim as Chief Executive Officer and President effective July 1, 2026, and approved a new employment agreement and equity award for him.
Under the agreement, he will receive an annual base salary of $850,000, a target annual cash bonus equal to 50% of base salary, and an annual grant of time-vesting restricted stock units (RSUs) targeted at approximately 50% of base salary. He will also receive an initial grant of 300,000 performance-based RSUs.
The initial RSUs vest on June 30, 2031 based on the 90-day average share price, with no vesting below $70 and full vesting at or above $100. The agreement provides severance-related COBRA subsidies, limited salary continuation on death or disability, and standard protective covenants, with accelerated RSU vesting upon certain change in control events or qualifying terminations.
Phibro Animal Health Corporation filed notices under Rule 144 reporting proposed sales of 281,600 shares of Class A Common Stock. The filing lists numerous smaller sales by BFI Co. LLC (repeated transactions of 1,760, 3,520 and other share lots on multiple dates).
The entries identify the broker Goldman Sachs & Co. LLC and show transaction dates in March–May 2026. The filing lists the sales as exchanges/private placement origins for the registered shares.
PHIBRO ANIMAL HEALTH CORP director E. Thomas Corcoran bought 10,000 shares of Class A Common Stock in an open-market purchase. The weighted average price was $31.77 per share, with trade prices ranging from $31.66 to $31.85.
After this transaction, he directly holds 41,459 shares, which includes 1,459 shares acquired through a dividend reinvestment plan sponsored by his broker.
BFI Co., LLC and Jack C. Bendheim filed an amended Schedule 13D for Phibro Animal Health, disclosing a new Rule 10b5-1 sales plan. The plan allows Goldman Sachs to sell up to 750,000 shares of Class A Common Stock through March 17, 2027, with the first possible trade date on September 16, 2026.
As of May 22, 2026, BFI beneficially owns 19,552,186 shares of common stock, equal to 48.2% of the Class A Common Stock on an as-converted basis, through 56,152 Class A shares and 19,496,034 Class B shares. If all plan shares are sold, BFI would still hold 56,152 Class A shares and 18,746,034 Class B shares.
Barclays PLC filed an amended Schedule 13G/A reporting beneficial ownership of 263,695 shares of Phibro Animal Health Corp-A common stock, representing 1.27% of the class. The filing shows Barclays has sole voting and sole dispositive power over the reported shares. The amendment is signed by a Barclays director on 05/14/2026.
Phibro Animal Health insider-related entity BFI Co., LLC sold a net 18,608 shares of Class A Common Stock in open-market transactions from May 5–7, 2026, at weighted average prices ranging from about $47 to $58 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted by BFI on December 11, 2025. BFI now holds 56,152 shares indirectly associated with President and CEO Jack Bendheim, who also directly holds 16,840 shares and disclaims beneficial ownership of BFI’s holdings beyond his pecuniary interest.
Phibro Animal Health Corporation reported solid growth for its third quarter ended March 31, 2026. Net sales were $383.5 million, up 10% from a year earlier, driven mainly by a 13% increase in Animal Health revenue to $291.2 million. Net income rose to $24.0 million, a 15% increase, and diluted EPS grew 16% to $0.59. Adjusted EBITDA was $60.8 million, up 11%, while adjusted net income reached $31.2 million and adjusted diluted EPS climbed 19% to $0.76.
Gross margin improved to 32.8% from 30.1%, reflecting higher volume, favorable mix and pricing. The company updated fiscal 2026 guidance to net sales of $1.46–$1.50 billion and adjusted EBITDA of $247–$255 million, noting higher midpoints across key measures. Phibro also highlighted a regulatory development in Brazil affecting certain antimicrobial products, a $125 million increase in its revolving credit facility to $435 million, and the launch of its Sustainable Solutions Platform, including VERRATAIN Verified Sustainability Solutions.
Phibro Animal Health delivered higher Q3 2026 results, with net sales of $383.5 million, up 10% from $347.8 million, and net income of $24.0 million versus $20.9 million. Diluted EPS rose to $0.59 from $0.51.
For the nine months, net sales climbed to $1.12 billion, up 22%, while net income more than doubled to $78.0 million, driven largely by the October 2024 Zoetis portfolio acquisition and strong Animal Health growth. Animal Health revenue reached $864.7 million, up 29%, led by medicated feed additives.
Leverage remains meaningful, with term loans of about $625.9 million and revolver borrowings of $115.0 million, pushing interest expense, net, to $34.2 million for the nine months. The company highlights geopolitical exposure in Israel and regulatory risks around carbadox in the U.S. and antimicrobial growth promoters in Brazil.
Phibro Animal Health Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.12 per share. The dividend applies to both its Class A and Class B common stock. It will be paid on June 24, 2026 to stockholders of record as of the close of business on June 3, 2026.